Use of lentivirus-like particles alone and in combination with live vaccinia-virus-based vaccines.
Panicali
D L
DL
Therion Biologics Corporation, Cambridge, MA 02142.
Mazzara
G
G
Sullivan
J L
JL
Hesselton
R
R
Shen
L
L
Letvin
N
N
Daniel
M
M
Desrosiers
R
R
Stott
E J
EJ
D016915:AIDS Vaccines / Q000276:immunology; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D005814:Genes, Viral; D005822:Genetic Vectors; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D007111:Immunity, Cellular; D008251:Macaca; D011817:Rabbits; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics* / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology
D016915:AIDS Vaccines; D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines